Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Arzneiverordnungen 2022 im Überblick Kapitel lesen Erstes Kapitel lesen

2023 | OriginalPaper | Buchkapitel

5. Hämatologische Neoplasien und solide Tumore

verfasst von : Prof. Dr. med. Wolf-Dieter Ludwig, Prof. Dr. med. Arnold Ganser, Prof. Dr. med. Georg Maschmeyer

Erschienen in: Arzneiverordnungs-Report 2023

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Auf einen Blick

Verordnungsprofil Das höchste Verordnungsvolumen unter den Onkologika haben erstmals in 2022 die monoklonalen Antikörper (30 %), gefolgt von den Hormonantagonisten zur Behandlung des Mammakarzinoms und des Prostatakarzinoms, auf die 25 % der definierten Tagesdosen (DDD) entfallen (Tab. 5.1). An dritter Stelle stehen die klassischen Zytostatika (22 %) mit der führenden Gruppe der Antimetabolite, was vor allem auf den häufigen Verordnungen von 5-Fluorouracil beruht. Als nächste Gruppen folgen Proteinkinaseinhibitoren, deren Verordnungsvolumen erneut leicht um 8,3 % gegenüber 2021 zugenommen hat. Führende Gruppe der monoklonalen Antikörper sind erneut Antikörper gegen PD-1-Rezeptoren und PD-L1-Liganden, die für ein stetig wachsendes Spektrum von onkologischen Indikationen zugelassen sind, gefolgt von HER2-Antikörpern zur Behandlung des HER2-positiven Mammakarzinoms. Die inzwischen verfügbaren 4 Biosimilars zu Trastuzumab übertreffen wie auch bereits in 2021 deutlich das Verordnungsvolumen des Originalpräparats (Herceptin). Führende Vertreter der Proteinkinaseinhibitoren hinsichtlich ihres Verordnungsvolumens sind die CDK-Inhibitoren für die Behandlung des hormonrezeptorpositiven, fortgeschrittenen Mammakarzinoms (4,2 Mio. DDD), gefolgt gleichauf (jeweils 3,5 Mio. DDD) von den BCR-ABL-Tyrosinkinaseinhibitoren zur Behandlung der chronischen myeloischen Leukämie sowie die Rezeptor-Tyrosinkinaseinhibitoren zur Behandlung u. a. des nicht-kleinzelligen Lungenkarzinoms, des Nierenzellkarzinoms, von gynäkologischen Tumoren (Mamma- bzw. Ovarialkarzinom) und Weichteilsarkomen, aber auch von nicht malignen Erkrankungen (z. B. idiopathische Lungenfibrose, interstitielle Lungenerkrankung). Einen Anstieg der Verordnungen zeigen auch die Bruton-Tyrosinkinaseinhibitoren, insbesondere Acalabrutinib zur Behandlung der chronischen lymphatischen Leukämie bzw. niedrig-maligner Lymphome (z. B. M. Waldenström), der Januskinaseinhibitor Ruxolitinib, die BRAF-/MEK-/, ALK- sowie die PARP-Inhibitoren sowie der BCL-2 Inhibitor Venclyxto. Weitere Proteinkinaseinhibitoren werden eingesetzt vor allem zur Behandlung der primären Myelofibrose (MF) und der nach Polycythämia Vera bzw. Essenzieller Thrombozythämie auftretenden MF.
Literatur
Abdel-Qadir H, Sabrie N, Leong D et al (2021) Cardiovascular risk associated with ibrutinib use in CLL. J Clin Oncol 39:3453–3462PubMedCrossRef
Abou-Alfa GK, Lau G, Kudo M et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21:671–684PubMedPubMedCentralCrossRef
Abou-Alfa GK, Lau G, Kudo M et al (2022) Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. N Eng J Med Evid 1(8)
André T, Meyerhardt J, Iveson T et al (2020a) Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 21:1620–1629PubMedPubMedCentralCrossRef
André T, Shiu KK, Kim TW et al (2020b) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383:2207–2218PubMedCrossRef
Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukaemia. Blood 127:2391–2405PubMedCrossRef
Baraibar I, Melero I, Ponz-Sarvise M, Castanon E (2019) Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer. Drug Saf 42:281–294PubMedCrossRef
Baraniskin A, Buchberger B, Pox C et al (2019) Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Eur J Cancer 106:37–44PubMedCrossRef
Barthélémy P, Rioux-Leclercq N, Thibault C et al (2021) Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data. Cancer Treat Rev 97:102191PubMedCrossRef
Bibeau K, Féliz L, Lihou CF et al (2022) Progression-free survival in patients with cholangiocarcinoma with or without FGF/FGFR alterations: a FIGHT-202 post hoc analysis of prior systemic therapy response. Jco Precis Oncol 6:e2100414PubMedPubMedCentralCrossRef
Booth CM, Sengar M, Goodman A et al (2023) Common sense oncology: outcomes that matter. Lancet Oncol 24:833–835PubMedCrossRef
Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy vs cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915–1928PubMedCrossRef
Byrd JC, Hillmen P, Ghia P et al (2021) Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 39:3441–3452PubMedPubMedCentralCrossRef
Camidge DR, Kim HR, Ahn MJ et al (2018) Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med 379:2017–2039CrossRef
Camidge DR, Kim HR, Ahn MJ et al (2021) Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol 16:2091–2108PubMedCrossRef
Chakiryan NH, Jiang DD, Gillis KA et al (2021) Real-world survival outcomes associated with first-line immunotherapy, targeted therapy, and combination therapy for metastatic clear cell renal cell carcinoma. JAMA Netw Open 4:e2111329PubMedPubMedCentralCrossRef
Chari A, Vogl DT, Gavriatopoulou M et al (2019) Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 38:727–738CrossRef
Chen AP, Sharon E, O’Sullivan-Coyne G et al (2023) Atezolizumab for advanced alveolar soft part sarcoma. N Engl J Med 389:911–992PubMedCrossRef
Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 359:613–626PubMedCrossRef
Chi KN, Agarwal N, Bjartell A et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13–24PubMedCrossRef
Choueiri TK, Escudier B, Powles T et al (2016) Cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17:917–927PubMedCrossRef
Choueiri TK, Hessel C, Halabi S et al (2018) Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer 94:115–125PubMedPubMedCentralCrossRef
Choueiri TK, Motzer RJ, Rini BI et al (2020) Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 31:1030–1039PubMedCrossRef
Choueiri TK, Powles T, Burotto M et al (2021) Checkmate 9ER investigators. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829–841PubMedPubMedCentralCrossRef
Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242PubMedCrossRef
Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 116:2040–2045PubMedPubMedCentralCrossRef
Conroy T, Hammel P, Hebbar M et al (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395–2406PubMedCrossRef
Cortes JE, Kim DW, Pinilla-Ibarz J et al (2018) Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132:393–404PubMedPubMedCentralCrossRef
Cortes JE, Heidel FH, Hellmann A et al (2019) Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 33:379–389PubMedCrossRef
Davis ID, Martin AJ, Stockler MR et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381:121–131PubMedCrossRef
Delforge M, Shah N, Miguel JSF et al (2022) Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv 6:1309–1318PubMedPubMedCentralCrossRef
Denkert C, Lebeau A, Schildhaus HU et al (2022) Neue Therapiemöglichkeiten beim metastasierten HER2-low-Mammakarzinom. Pathologie 43:457–466PubMedCrossRef
Der Arzneimittelbrief (2019) Chronische lymphatische Leukämie: Erstlinientherapie mit neuen Wirkstoffen. AMB 53:49
Der Arzneimittelbrief (2020) Ibrutinib: neue Erkenntnisse zu kardiovaskulären Nebenwirkungen unter „Real-World“-Bedingungen. AMB 54:1
Dickinson MJ, Carlo-Stella C, Morschhauser F et al (2022) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 387:2220–2231PubMedCrossRef
Di Leo A, Jerusalem G, Petruzelka L et al (2014) Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 106:djt337PubMedCrossRef
Dimopoulos MA, Oriol A, Nahi H et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375:1319–1331PubMedCrossRef
Dimopoulos MA, Goldschmidt H, Niesvizky R et al (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18:1327–1337PubMedCrossRef
Dimopoulos MA, Lonial S, White D et al (2020) Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 10:91PubMedPubMedCentralCrossRef
Dimopoulos MA, Moreau P, Terpos E et al (2021) Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. HemaSphere 5:e528PubMedPubMedCentral
Dimopoulos MA, Hungria VTM, Radinoff A et al (2023) Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol 10:e801–e812PubMedCrossRef
DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617–629PubMedCrossRef
Dobbelstein M, Moll U (2014) Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov 13:179–196PubMedCrossRef
Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21:271–282PubMedCrossRef
Douillard JY, Oliner KS, Siena S et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034PubMedCrossRef
Dreger P, Ghia P, Schetelig J et al (2018) High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood 132:892–902PubMedCrossRef
Drilon A, Oxnard GR, Tan DSW et al (2020) Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 383:813–824PubMedPubMedCentralCrossRef
Durie BG, Hoering A, Abidi MH et al (2017) Bortezomib with lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519–527PubMedCrossRef
Duell J, Maddocks KJ, González-Barca E et al (2021) Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 106:2417–2426PubMedPubMedCentralCrossRef
Dy GK, Govindan R, Velcheti V et al (2023) Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100. J Clin Oncol 41:3311–3317PubMedPubMedCentralCrossRef
Eichhorst B, Niemann CU, Kater AP et al (2023) First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med 388:1739–1754PubMedCrossRef
Ellis MJ, Llombart-Cussac A, Feltl D et al (2015) Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol 33:3781–3787PubMedPubMedCentralCrossRef
Erkaliskan A, Erdogan DS, Eskazan AE (2021) Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood Adv 5:3344–3353CrossRef
Etienne G, Guilhot J, Rea D et al (2017) Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 35:298–305PubMedCrossRef
Facon T, Dimopoulos MA, Dispenzieri A et al (2018) Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131:301–310PubMedPubMedCentralCrossRef
Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232PubMedPubMedCentralCrossRef
Fenaux P, Platzbecker U, Mufti GJ et al (2020) Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 382:140–151PubMedCrossRef
Ferris RL, Blumenschein G Jr, Fayette J (2018) Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81:45–51PubMedPubMedCentralCrossRef
Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925–1936PubMedCrossRef
Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894–1905PubMedCrossRef
Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352–360PubMedCrossRef
Fizazi K, Shore N, Tammela TL et al (2019) Daralutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380:1235–1246PubMedCrossRef
Franzen N, Romagnoli G, Ziegler A et al (2022) Improving the affordability of anticancer medicines demand evidence-based solutions. Cancer Discov 12:299–302PubMedCrossRef
Gainor JF, Curigliano G, Kim DW et al (2021) Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol 22:959–969PubMedCrossRef
Gellad WF, Kesselheim AS (2017) Accelerated approval and expensive drugs – A challenging combination. N Engl J Med 376:2001–2004PubMedCrossRef
Ghia P, Pluta A, Wach M et al (2020) ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 38:2849–2861PubMedCrossRef
Gisslinger H, Klade C, Georgiev P et al (2020) Ropeginterferon alfa 2-b versus standard therapy for plycythemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 7:e196–e208PubMedCrossRef
Goldman JW, Dvorkin M, Chen Y et al (2021) Durvalumab, with or without tremelimumab, plus platinum-etoposide vs platinum-etoposide alone in first-line treatment of extensive-stage SCLC (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 22:51–65PubMedCrossRef
Goldschmidt H, Ashcroft J, Szabo Z et al (2019) Navigating the treatment landscape in multiple myeloma: which combinations to use and when? Ann Hematol 98:1–18PubMedCrossRef
Goss GD, Cobo M, Lu S et al (2021) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. EClinicalMedicine 37:100940PubMedPubMedCentralCrossRef
Greenberg PL, Tuechler H, Schanz J et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465PubMedPubMedCentralCrossRef
Griesinger F, Curigliano G, Thomas M (2022) Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol 33:1168–1178PubMedCrossRef
Grosicki S, Simonova M, Spicka I et al (2020) Once-per-week selinexor, bortezomib, and dexamethasone vs twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 396:1563–1573PubMedCrossRef
Guglielmelli P, Vannucchi AM (2020) Current management strategies for polycythemia vera and essential thrombocythemia. Blood Rev 42:100714PubMedCrossRef
Guigay J, Aupérin A, Fayette J et al (2021) Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 22:463–475PubMedCrossRef
Hall ME, Huelster HL, Luckenbaugh AN et al (2020) Metastatic hormone-sensitive prostate cancer: current perspective on the evolving therapeutic landscape. Onco Targets Ther 13:3571–3581PubMedPubMedCentralCrossRef
Hallek M, Shanafelt TD, Eichhorst B (2018) Chronic lymphocytic leukaemia. Lancet 391:1524–1537PubMedCrossRef
Hanna NH, Robinson AG, Temin S et al (2021) Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol 39:1040–1091PubMedCrossRef
Harrison CN, Campbell PJ, Buck G et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33–45PubMedCrossRef
Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365PubMedCrossRef
Heuser M, Ofran Y, Boissel N et al (2020) Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:697–712PubMedCrossRef
Hochhaus A, Larson RA, Guilhot F et al (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376:917–927PubMedPubMedCentralCrossRef
Hochhaus A, Baccarani M, Silver RT et al (2020a) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966–984PubMedPubMedCentralCrossRef
Hochhaus A, Breccia M, Saglio G et al (2020b) Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia 34:1495–1502PubMedPubMedCentralCrossRef
Hortobagyi GN, Stemmer SM, Burris HA et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738–1748PubMedCrossRef
Horwitz S, O’Connor OA, Pro B et al (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393:229–240PubMedCrossRef
Howell A, Robertson JFR, Quaresma AJ et al (2002) Fulvestrant (ICI 182,780) is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing progressing after prior endocrine treatment. J Clin Oncol 20:3396–3403PubMedCrossRef
Howell A, Robertson JF, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22:1605–1613PubMedCrossRef
Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef
Hutchings M, Mous R, Clausen MR et al (2019) Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet 398(10306):1157–1169CrossRef
Iversen P, McLeod DG, See WA et al (2010) Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide early prostate cancer program at a median follow-up of 9.7 years. BJU Int 105:1074–1081PubMedCrossRef
Jabbour E, Kantarjian H (2018) Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 93:442–459PubMedCrossRef
James ND, de Bono JS, Spears MR et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338–351PubMedPubMedCentralCrossRef
Johnson ML, Cho BC, Luft A et al (2023) Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol 41:1213–1227PubMedCrossRef
Joppi R, Gerardi C, Bertele V et al (2016) Letting post-marketing bridge the evidence gap: the case of orphan drugs. BMJ 353:i2978PubMedCrossRef
Kantarjian H, DeAngelo DJ, Stelljes M et al (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375:740–753PubMedPubMedCentralCrossRef
Kantarjian H, Stein A, Gökbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:836–847PubMedPubMedCentralCrossRef
Kantarjian HM, Welch MA, Jabbour E (2023) Revisiting six established practices in the treatment of chronic myeloid leukaemia. Lancet Haematol 10:e860–e864PubMedCrossRef
Kastritis E, Terpos E, Dimopoulos MA (2022) How I treat relapsed multiple myeloma. Blood 139:2904–2917PubMedCrossRef
Kinsey EN, Zhang T, Armstrong AJ (2020) Metastatic hormone-sensitive prostate cancer. A review of the current treatment landscape. Cancer J 26:64–75PubMedCrossRef
Knipper S, Ott S, Schlemmer H-P et al (2021) Kurative Therapieoptionen des lokal begrenzten Prostatakarzinoms. Dtsch Ärztebl 118:228–235
Kröger NM, Deeg JH, Olavarria E et al (2015) Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia 29:2126–2133PubMedCrossRef
Kumar SK, Jacobus SJ, Cohen AD et al (2020) Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21:1317–1330PubMedPubMedCentralCrossRef
Kudo M, Finn RS, Qin S et al (2018) Lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173PubMedCrossRef
Lambert J, Pautas C, Terré C et al (2019) Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 104:113–119PubMedPubMedCentralCrossRef
Lancet JE, Uy GL, Cortes JE et al (2018) CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary Acute Myeloid Leukemia. J Clin Oncol 36:2684–2692PubMedPubMedCentralCrossRef
Ledermann JA, Harter P, Gourley C et al (2016) Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 17:1579–1589PubMedCrossRef
Liu SV, Reck M, Mansfield AS et al (2021) Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 39:619–630PubMedPubMedCentralCrossRef
Lonial S, Nooka AK, Thulasi P et al (2021) Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J 11:103PubMedPubMedCentralCrossRef
Lyman GH, Moses HL (2016) Biomarker tests for molecularly targeted therapies – the key to unlocking precision medicine. N Engl J Med 375:4–6PubMedCrossRef
Ma YY, Zhao M, Liu Y et al (2019) Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis. Hematology 24:507–515PubMedCrossRef
Madhusoodanan J (2023) Fast-track troubles: How US drug policy could be harming people with cancer around the world. Nature 620:264–267PubMedCrossRef
Martin T, Usmani SZ, Berdeja JG et al (2023) Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 41:1265–1274PubMedCrossRef
Mateos MV, Cavo M, Blade J et al (2020) Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395:132–141PubMedCrossRef
Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909–1919PubMedCrossRef
McCarthy PL, Holstein SA, Petrucci MT et al (2017) Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 35:3279–3289PubMedPubMedCentralCrossRef
Miles D, Gligorov J, André F et al (2021) Primary results from IMpassion131, a double-blind, placebo-controlled randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metatstatic triple-negative breast cancer. Ann Oncol 32:9945–1004CrossRef
Mirza MR, Monk BJ, Herrstedt J et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 376:2154–2164CrossRef
Mok T, Camidge DR, Gadgeel SM et al (2020) Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 31:1056–1064PubMedCrossRef
Montero A, Fossella F, Hortobagyi G et al (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6:229–239PubMedCrossRef
Moreau P, Masszi T, Grzasko N et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374:1621–1634PubMedCrossRef
Moreau P, Dimopoulos MA, Mikhael J et al (2021) Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 397:2361–2371PubMedCrossRef
Mori K, Miura N, Mostafaei H et al (2020) Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 23:539–548PubMedCrossRef
Moro-Sibilot D, Cozic N, Pérol M et al (2019) Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol 30:1985–1991PubMedCrossRef
Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590PubMedPubMedCentralCrossRef
Motzer RJ, Hutson TE, Cella D et al (2013a) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722–731PubMedCrossRef
Motzer RJ, Nosov D, Eisen T et al (2013b) Tivozanib vs sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 31:3791–3799PubMedPubMedCentralCrossRef
Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103–1115PubMedPubMedCentralCrossRef
Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289–1300PubMedCrossRef
Motzer R, Porta C, Alekseev B et al (2022) Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol 23:768–780PubMedPubMedCentralCrossRef
Mullard A (2021) 2020 FDA drug approvals. Nature Rev Drug Discov 20:85–90CrossRef
Munshi NC, Anderson LD Jr, Shah N et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384:705–716PubMedCrossRef
Najjar M, McCarron J, Cliff ERS et al (2023) Adverse event reporting in randomized clinical trials for multiple myeloma. Jama Netw Open 6:e2342195PubMedPubMedCentralCrossRef
Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024PubMedCrossRef
O’Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004PubMedCrossRef
Oh DY, He AR, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. N Eng J Med Evid 1(8)
Osborne CK, Pippen J, Jones SE et al (2002) A double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant with anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a north American trial. J Clin Oncol 20:3386–3395PubMedCrossRef
Özgüroğlu M, Kilickap S, Sezer A et al (2023) First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol 24:989–1001PubMedCrossRef
Paik PK, Felip E, Veillon R et al (2020) Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med 383:931–943PubMedPubMedCentralCrossRef
Palumbo A, Mina R (2013) Management of older adults with multiple myeloma. Blood Rev 27:133–142PubMedCrossRef
Palumbo A, Chanan-Khan A, Weisel K et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375:754–766PubMedCrossRef
Pardanani A, Tefferi A (2018) How I treat myelofibrosis after failure of JAK inhibitors. Blood 132:492–500PubMedCrossRef
Pardanani A, Tefferi A, Masszi T et al (2021) Updated results of the placeo-controlled, phaseIII JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. Br J Haematol 195:244–248PubMedPubMedCentralCrossRef
Pemmaraju N, Lane AA, Sweet KL et al (2019) Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med 380:1628–1637PubMedCrossRef
Perl AE et al (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 381:1728–1740PubMedCrossRef
Pfirrmann M, Clark RE, Prejzner W et al (2020) The EUTOS long-term survival (ELTS) score is superior to the Sokal score for prediting survival in chronic myeloid leukemia. Leukemia 34:2138–2149PubMedPubMedCentralCrossRef
Platzbecker U, Porta DMG, Santini V et al (2023) Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet 402:373–385PubMedCrossRef
Plimack ER, Powles T, Stus V et al (2023) Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study. Eur Urol 84:449–454PubMedCrossRef
Powles T, Plimack ER, Soulières D et al (2020) Pembrolizumab plus axitinib vs sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 21:1563–1573PubMedCrossRef
Powles T, Tomczak P, Park SH et al (2022) Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23:1133–1144PubMedCrossRef
Prasad V, Mailankody S (2017) Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 177:1569–1575PubMedPubMedCentralCrossRef
Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20:663–673PubMedCrossRef
Pujade-Lauraine E, Ledermann JA, Selle F et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18:1274–1284PubMedCrossRef
Raab MS, Cavo M, Delforge M et al (2016) Multiple myeloma: practice patterns across Europe. Br J Haematol 175:66–76PubMedCrossRef
Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95:548–567PubMedCrossRef
Rajkumar SV, Kyle RA (2016) Progress in myeloma – a monoclonal breakthrough. N Engl J Med 375:1390–1392PubMedCrossRef
Ramalingam SS, Vansteenkiste J, Planchard D et al (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41–50PubMedCrossRef
Rassaf T, Totzeck M, Backs J et al (2020) Onco-cardiology: consensus paper of the German cardiac society, the German society for pediatric cardiology and congenital heart defects and the German society for hematology and medical oncology. Clin Res Cardiol 109:1197–1222PubMedPubMedCentralCrossRef
Réa D, Mauro MJ, Boquimpani C et al (2021) A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138:2031–2041PubMedPubMedCentralCrossRef
Reck M, Kaiser R, Mellemgaard A et al (2014) Docetaxel plus nintedanib vs docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15:143–155PubMedCrossRef
Richardson PG, Kumar SK, Masszi T et al (2021) Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 39:2430–2442PubMedCrossRef
Richardson PG, Perrot A, San-Miguel J et al (2022) Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol 23:416–427PubMedCrossRef
Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116–1127PubMedCrossRef
Rini BI, Pal SK, Escudier BJ et al (2020) Tivozanib vs sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol 21:95–104PubMedCrossRef
Robertson JF, Llombart-Cussac A, Rolski J et al (2009) Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 27:4530–4535PubMedCrossRef
Rosario DJ, Davey P, Green J et al (2016) The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. World J Urol 34:1601–1609PubMedPubMedCentralCrossRef
Rugo HS (2019) Achieving improved survival outcomes in advanced breast cancer. N Engl J Med 381:371–372PubMedCrossRef
Rugo HS, Bardia A, Marmé et al (2023) Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 402:1423–1433PubMedCrossRef
Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152–160PubMedCrossRef
Salem JE, Manouchehri A, Bretagne M et al (2019) Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol 74:1667–1678PubMedCrossRef
San Miguel J, Weisel K, Moreau P et al (2013) Pomalidomide plus low-dose dexamethasone vs high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14:1055–1066PubMedCrossRef
Sartor O, de Bono JS (2018) Metastatic prostate cancer. N Eng J Med 378:645–657CrossRef
Sauer R, Becker H, Hohenberger W et al (2004) Preoperative vs postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRef
Saussele S, Richter J, Guilhot J et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised trial. Lancet Oncol 19:747–757PubMedCrossRef
Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197PubMedCrossRef
Schilsky RL (2018) A new IDEA in adjuvant chemotherapy for colon cancer. N Engl J Med 378:1242–1244PubMedCrossRef
Sehn LH, Herrera AF, Flowers CR et al (2020) Polatuzumab vedotin in relapsed of refractory diffuse large B-cell lymphoma. J Clin Oncol 38:155–165PubMedCrossRef
Shragai T, Magen H, Lavi N et al (2023) Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multicentre retrospective study. Br J Haematol 200:45–53PubMedCrossRef
Sharma A, Dwary AD, Mohanti BK et al (2010) Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 28:4581–4586PubMedCrossRef
Shitara K, Bang YJ, Iwasa S et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive Gastric cancer. N Engl J Med 382:2419–2430PubMedCrossRef
Shroff RT, Kennedy EB, Bachini M et al (2019) Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol 37:1015–1027PubMedCrossRef
Siegel DS, Dimopoulos MA, Ludwig H et al (2018) Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 36:728–734PubMedCrossRef
Silverman LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429–2440PubMedCrossRef
Slamon DJ, Neven P, Chia S et al (2020) Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 382:514–524PubMedCrossRef
Solomon JP, Linkov I, Rosado A et al (2020) NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 33:38–46PubMedCrossRef
Solomon BJ, Bauer TM, Mok TSK et al (2023) Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med 11:354–366PubMedCrossRef
Soria JC, Felip E, Cobo M et al (2015) Afatinib vs erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 16:897–907PubMedCrossRef
Steegmann JL, Baccarani M, Breccia M et al (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30:1648–1671PubMedPubMedCentralCrossRef
Stone RM, Mandrekar SJ, Sanford BL et al (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377:454–464PubMedPubMedCentralCrossRef
Tang J, Shalabi A, Hubbard-Lucey VM (2018) Comprehensive analysis of the clinical immune-oncology landscape. Ann Oncol 29:84–91PubMedCrossRef
Tannock IF, Hickman JA (2016) Limits to personalized medicine. N Engl J Med 375:1289–1294PubMedCrossRef
Tay-Teo K, Hill SR (2019) Comparison of sales income and research and development costs for FDA-approved cancer drugs sold by originator drug companies. JAMA Netw Open 2(1):e186875PubMedPubMedCentralCrossRef
Tew WP, Lacchetti C, Ellis A et al (2020) PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol 38:3468–2493PubMedCrossRef
Tewari KS, Burger RA, Enserro D et al (2019) Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol 37:2317–2328PubMedPubMedCentralCrossRef
Tilly H, Morschhauser F, Sehn LH et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386:351–363PubMedCrossRef
Thol F, Schlenk RF (2014) Gemtuzumab ozogamicin in acute myeloid leukemia revisited. Expert Opin Biol Ther 14:1185–1195PubMedCrossRef
Turner NC, Slamon DJ, Ro J et al (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379:1926–1936PubMedCrossRef
Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine vs gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281PubMedCrossRef
Van Cutsem E, Köhne CH, Láng I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019PubMedCrossRef
Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422PubMedCrossRef
Vannucchi AM, Kiladjian JJ, Griesshammer M et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372:426–435PubMedPubMedCentralCrossRef
Varga C, Maglio M, Ghobrial IM et al (2018) Current use of monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 181:447–459PubMedCrossRef
Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127PubMedCrossRef
Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799–807PubMedPubMedCentralCrossRef
Verstovsek S, Gotlib J, Mesa RA et al (2017) Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 10:156PubMedPubMedCentralCrossRef
Vitolo U, Trneny M, Belada D et al (2017) Obinutuzmab or rituximab plus cyclophosphamide, doxorubin, vincristine and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol 35:3529–3537PubMedCrossRef
Vogler S, Panteli D, Busse R (2021) Biologika und Biosimilars in Deutschland und im europäischen Vergleich – Marktsteuerungsmechanismen und Preisvergleich. In: Ludwig WD, Mühlbauer B, Seifert R (Hrsg) Arzneiverordnungs-Report 2021. Springer, Berlin
Vokinger KN, Hwang TJ, Grischott T et al (2020) Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol 21:664–670PubMedCrossRef
Vokinger KN, Hwang TJ, Daniore P et al (2021) Analysis of Launch and postapproval cancer drug pricing, clinical benefit and policy implications in the US and Europe. JAMA Oncol 7:e212026PubMedPubMedCentralCrossRef
Vokinger KN (2022) Beschleunigte Zulassungen und therapeutischer Nutzen von Arzneimitteln in den USA und Europa. In: Ludwig WD, Mühlbauer B, Seifert R (Hrsg) Arzneiverordnungs-Report 2022. Springer, Berlin
Vokinger KN, Hwang TJ, Carl DI et al (2022) Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. Lancet Oncol 23:514–520PubMedCrossRef
Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721–1728PubMedPubMedCentralCrossRef
Waxman AJ, Clasen S, Hwang WT et al (2018) Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol 4:e174519PubMedCrossRef
Wei AH, Döhner H, Pocock C et al (2020) Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 383:2526–2537PubMedCrossRef
Wolf J, Seto T, Han JY et al (2020) Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med 383:944–957PubMedCrossRef
Yang JC, Wu YL, Schuler M et al (2015) Afatinib vs cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16:141–151PubMedCrossRef
Franzen N, Retel V, Schats W, van Harten WH (2020) Evidence underlying policy proposals for sustainable anticancer drug prices. JAMA Oncol 6:906–916CrossRef
Metadaten
Titel
Hämatologische Neoplasien und solide Tumore
verfasst von
Prof. Dr. med. Wolf-Dieter Ludwig
Prof. Dr. med. Arnold Ganser
Prof. Dr. med. Georg Maschmeyer
Copyright-Jahr
2023
Verlag
Springer Berlin Heidelberg
Buch
Arzneiverordnungs-Report 2023

Print ISBN: 978-3-662-68370-5

Electronic ISBN: 978-3-662-68371-2

Copyright-Jahr: 2023

DOI
https://doi.org/10.1007/978-3-662-68371-2_5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise